Why does the xenon room need negative pressure?

Negative pressure relative to adjacent corridors and rooms ensures that if xenon escapes the trap or spirometer, room air flows inward rather than outward, keeping the gas from spreading to occupied areas. The room air is then exhausted through a controlled path, ideally directly to the outside above the roofline or through the trap system.

Xenon-133 Ventilation Study Radiation Safety

Q: Why is a xenon-133 ventilation study a radiation safety concern?

Xe-133 is a radioactive noble gas that the patient inhales and then exhales back into the room. Because it is a gas, it becomes an airborne inhalation and submersion hazard rather than a surface contaminant. A release fills the room air, so radiation safety relies on containing the gas with a xenon trap, keeping the room at negative pressure, and controlling exhaust rather than on wipe tests alone.

Q: What airborne limit applies to Xe-133?

10 CFR Part 20 Appendix B lists a derived air concentration for Xe-133 as a submersion value, reflecting external dose from the surrounding cloud rather than internal deposition. Occupational exposure is controlled to the derived air concentration and ALARA, and releases to the environment are controlled to the effluent concentration limits in the same appendix.

Q: What should staff do if xenon is released into the room?

Because Xe-133 is an inert gas that is not retained in the body and clears quickly, the response to a room release centers on ventilation and evacuation: leave the room, let the exhaust ventilation dilute and clear the gas, and re-enter once concentrations fall below the applicable limits. The gas does not fix to surfaces the way particulate contamination does, so dilution and time are the primary controls.

Q: How is Xe-133 different from Technegas or aerosol ventilation agents?

Technetium-labeled DTPA aerosol and Technegas are particulate agents that deposit in the lungs and are handled as particulate contamination, while Kr-81m is an ultrashort-lived gas. Xe-133 is a longer-lived true gas that is exhaled and must be trapped or exhausted, which is why xenon studies carry gas-handling requirements the particulate agents do not.

A xenon-133 lung ventilation study introduces a radioactive noble gas that the patient inhales and then breathes back out into the room — turning the exam into a gas-handling problem rather than an ordinary radiopharmaceutical procedure. Because Xe-133 is a gas, its radiation safety hinges on containing exhaled activity in a xenon trap, keeping the imaging room under negative pressure, controlling the building exhaust, and respecting the airborne-concentration limits in 10 CFR Part 20.¹²⁴

Unlike a spilled vial of liquid activity, released Xe-133 does not stay put. It fills the air, becomes an inhalation and submersion hazard, and travels with the ventilation. A defensible radiation safety program treats the gas, the room, and the exhaust as one engineered system.⁴⁶

Introduction

Most nuclear medicine radiation safety centers on liquids and solids — vials, syringes, and surface contamination — but a xenon ventilation study breaks that mold. Xe-133 is delivered as a gas, administered through a closed spirometer while the patient rebreathes, and then exhaled. Any gas that escapes the closed system enters the room air, where it exposes staff externally (submersion in the cloud) and, to a lesser degree, internally.

That difference drives the entire safety design. Wipe tests, absorbent pads, and the usual spill kit are the wrong tools for a gas. Instead, the controls are engineered: a charcoal xenon trap to capture exhaled activity, a room held at negative pressure so leaks flow inward, and a controlled exhaust path so any released gas is diluted and vented safely. These are the elements a medical physicist and radiation safety officer must specify, verify, and document.

This article explains the physics of Xe-133, why a gas behaves so differently from particulate agents, the engineering and administrative controls that keep exposures low, the airborne limits from 10 CFR Part 20, a worked room-clearance calculation, and the regulatory framework. It complements our guides to radioactive gas handling and effluent control and airborne radioactivity area ventilation controls.

Topic Explanation

The radionuclide: xenon-133

Xe-133 is a radioactive isotope of the inert noble gas xenon, produced as a fission product and supplied as a gas for inhalation lung imaging. Its key physical properties, from standard decay-data compilations, are a physical half-life of about 5.24 days, decay by beta emission with a maximum beta energy near 0.35 MeV, and a principal imaging gamma ray at approximately 81 keV with an emission intensity around 37%.⁷ The 81 keV photon is well matched to a gamma camera fitted with a low-energy collimator, which is why Xe-133 has long served as a ventilation agent paired with a Tc-99m macroaggregated-albumin perfusion study.⁴⁵

Two properties make Xe-133 a distinctive hazard. First, it is a gas at room temperature, so it disperses into air rather than settling on surfaces. Second, it is chemically inert and poorly soluble in blood, so an inhaled dose is largely exhaled within minutes rather than retained — the washout that ventilation imaging depends on also means the patient promptly returns the activity to the room.⁴

Why a gas is a different problem

A radioactive gas creates an airborne hazard governed by concentration in air, not by surface contamination. The relevant exposure pathways are:

Submersion (external) dose from being immersed in a cloud of Xe-133; because the gas is external and its gamma is only 81 keV, this is the dominant occupational concern, and it scales with air concentration and time.
Inhalation (internal) dose, which is limited because inert xenon is not appreciably retained.

Because the hazard is airborne, the controls are ventilation-based. This is fundamentally different from a Tc-99m aerosol or Technegas study, where the agent is a particulate that deposits in the lungs and is managed as particulate contamination, or from Kr-81m, an ultrashort-lived gas (about 13-second half-life) that decays almost immediately.⁵ Xe-133's multi-day half-life means released gas persists long enough to require active capture or controlled exhaust — the reason gas handling appears in a facility's ALARA program and airborne-controls planning.

The engineered controls

A xenon ventilation program is built around three engineered elements:⁴⁶

The xenon trap. A canister of activated charcoal adsorbs exhaled Xe-133 from the spirometer's exhaust so it is captured rather than released. The loaded trap is stored as radioactive material and allowed to decay.
The negative-pressure room. The imaging room is maintained at negative pressure relative to adjacent areas so that any leak draws room air inward, preventing spread to corridors and occupied spaces.
The controlled exhaust. Room air (and, in some designs, spirometer exhaust) is vented through a dedicated path — ideally directly to the outdoors above the roofline, or through the trap — rather than recirculated.

These are supported by administrative controls: a well-maintained closed spirometer, staff training, area monitoring, and a clear response plan for a release.

Key Technical Principles

Airborne concentration and the DAC

Occupational exposure to an airborne radionuclide is controlled to its derived air concentration (DAC), the concentration that would deliver a limiting dose over 2,000 working hours. For Xe-133, 10 CFR Part 20 Appendix B lists the occupational DAC as a submersion value — meaning it is based on external dose from the surrounding cloud rather than internal deposition — equal to $1 \times 1 0^{- 4} μ Ci/mL$ (about $3.7 \times 1 0^{6} Bq/m^{3}$ ).¹ Releases to the environment are separately controlled to the effluent concentration limit, listed for Xe-133 as $5 \times 1 0^{- 7} μ Ci/mL$ in air.¹

Cumulative intake and submersion are tracked in DAC-hours, where one DAC-hour is one hour spent in a concentration of one DAC. Fifty percent of the annual limit corresponds to 1,000 DAC-hours; keeping routine exposures well below this and as low as reasonably achievable is the operational goal.¹³

Diluting a release with ventilation

When gas enters a ventilated room, its concentration decays exponentially at a rate set by the air-change rate. For a well-mixed room with volume $V$ and ventilation flow $Q$ , the air-change rate is $k = Q / V$ (air changes per unit time), and the concentration after a release of initial concentration $C_{0}$ (with no continuing source) is:

C (t) = C_{0} e^{- k t}

The time to fall from $C_{0}$ to a target concentration $C$ is:

t = \frac{1}{k} ln (\frac{C _{0}}{C})

Worked room-clearance example

Suppose a full 740 MBq (20 mCi) dose of Xe-133 is accidentally released into a well-mixed ventilation room of volume $V = 30 m^{3}$ . The initial airborne concentration is:

C_{0} = \frac{740 MBq}{30 m ^{3}} \approx 24.7 MBq/m^{3}

Comparing to the occupational DAC of about $3.7 MBq/m^{3}$ (that is, $1 \times 1 0^{- 4} μ Ci/mL$ ):

\frac{C _{0}}{DAC} = \frac{24.7}{3.7} \approx 6.7

so the initial concentration is roughly 6.7 times the DAC. With a room ventilation rate of $k = 10$ air changes per hour, the time to dilute the concentration down to one DAC is:

t = \frac{1}{10 h ^{- 1}} ln (6.7) \approx 0.19 h \approx 11 minutes

This illustrates why the correct response to a xenon release is to evacuate and let ventilation clear the room: with adequate exhaust, airborne concentrations fall below the occupational limit in minutes. It also shows why a room with poor ventilation, or a recirculating system, is unacceptable for xenon work — the same driver behind the exhaust requirements discussed in our effluent-control guide.

Comparing ventilation agents

Agent	Physical half-life	Form	Primary hazard	Room / exhaust need
Xenon-133	~5.24 days⁷	Inert gas	Submersion (airborne)¹	Trap + negative pressure + controlled exhaust⁴
Krypton-81m	~13 seconds⁵	Inert gas	Minimal — decays at once	Generator-based, little containment
Tc-99m DTPA aerosol	~6 hours	Particulate aerosol	Particulate contamination	Aerosol containment, spill controls
Technegas (Tc-99m)	~6 hours	Carbon nanoparticle	Particulate contamination	Aerosol containment, spill controls

The table makes the point plainly: Xe-133 is the outlier whose multi-day half-life and gaseous form demand engineered capture and exhaust that the particulate and ultrashort-lived agents do not.⁵

Clinical Impact

Radiation safety design directly affects whether a facility can offer xenon ventilation imaging at all — and how safely. The practical consequences include:

Staff dose. With a working trap, negative-pressure room, and controlled exhaust, technologist doses from routine xenon studies are low. The exposure that occurs is almost entirely external submersion during any brief release, so minimizing leaks and time in a contaminated room is the key protective action.⁴
Facility siting. A xenon room must be located and ducted so its exhaust does not re-enter the building air intake or expose occupied areas above, below, or adjacent to it — a design constraint that shapes department layout.
Waste handling. Loaded charcoal traps and any contaminated components are radioactive material subject to decay-in-storage and waste procedures, adding a small but real operational burden.²
Continuity of service. Because many centers have shifted to Tc-99m aerosols, Technegas, or Kr-81m, a facility that retains Xe-133 must maintain the specialized ventilation infrastructure and training to keep it compliant.⁵

Where xenon imaging is retained, its physics performance — the 81 keV photon and washout kinetics that make it a good functional ventilation agent — is inseparable from the safety infrastructure that contains the gas, a theme we develop in the V/Q lung scintigraphy physics overview.

Practical Optimization Tips

Maintain the closed system

The single most effective control is a leak-free spirometer and trap. Inspect the rebreathing circuit, valves, mouthpiece seal, and trap connections before each study, and follow the manufacturer's maintenance schedule. A well-maintained closed system prevents most releases before they start.

Verify negative pressure and exhaust

Confirm that the room is actually at negative pressure relative to adjacent spaces — a smoke check or manometer reading, not an assumption — and that the exhaust vents where intended. Re-verify after any HVAC work, because balancing changes can silently reverse a room's pressure relationship.

Monitor the air

Use an appropriately calibrated, energy-suitable area monitor to detect elevated airborne activity, and establish an alarm or action level. Because the hazard is airborne, air monitoring — not surface wipes — is the meaningful measurement, a point that ties directly to airborne radioactivity area controls.

Plan the release response in advance

Post a simple, xenon-specific procedure: on a suspected release, stop the study, evacuate the room, allow ventilation to clear the gas, and re-enter only after concentrations fall below the action level. Because inert xenon is exhaled and not retained, dilution and time — not decontamination — are the correct response, distinguishing a gas release from a radioactive material spill.

Manage trap decay and disposal

Track loaded traps as radioactive material, store them for decay, and dispose of them under the facility's waste program. Label and inventory traps so a "hot" trap is never mistaken for a fresh one.

Regulatory Considerations

Xenon ventilation work sits within NRC (or Agreement State) byproduct-material regulation, with airborne limits and engineering-control expectations set by 10 CFR Part 20 and licensing guidance in NUREG-1556. The framework includes:

Airborne and effluent limits. 10 CFR Part 20 sets occupational dose limits, the DAC concept, and effluent concentration limits; Appendix B lists the Xe-133 submersion DAC and air effluent value, and 10 CFR 20.1701 favors process or engineering controls (such as the trap and exhaust) over reliance on respiratory protection.¹
ALARA and program requirements. The radiation protection program under 10 CFR 20.1101 must keep doses as low as reasonably achievable, which for xenon means maintaining containment and ventilation rather than accepting routine releases.¹³
Medical use and licensing. Possession and medical use of Xe-133 fall under 10 CFR Part 35, and NRC NUREG-1556 Volume 9 provides program-specific licensing guidance, including expectations for gaseous-material handling, trap use, and room ventilation.²
State and jurisdictional variation. DRPS serves clients across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware — a mix of NRC Agreement States and direct-NRC jurisdictions (Washington DC and Delaware) — so specific license conditions for xenon rooms should always be confirmed with the authority having jurisdiction.

Documented ventilation verification, trap management, air-monitoring records, and a written release procedure are what make a xenon program defensible during inspection.²⁶

Frequently Asked Questions (FAQs)

Why is a xenon-133 ventilation study a radiation safety concern?

Xe-133 is a radioactive noble gas the patient inhales and exhales into the room. Because it is a gas, it becomes an airborne inhalation and submersion hazard rather than a surface contaminant, so safety relies on trapping the gas, holding the room at negative pressure, and controlling exhaust rather than on wipe tests.¹⁴

What is a xenon trap?

A xenon trap is a canister of activated charcoal that adsorbs exhaled Xe-133 from the rebreathing system so the gas is captured rather than released. The trapped xenon decays in the charcoal, and the trap is handled and stored as radioactive material until it has decayed.⁴

What airborne limit applies to Xe-133?

10 CFR Part 20 Appendix B lists the Xe-133 occupational DAC as a submersion value of $1 \times 1 0^{- 4} μ Ci/mL$ , reflecting external dose from the surrounding cloud, and an air effluent concentration limit of $5 \times 1 0^{- 7} μ Ci/mL$ . Exposures are controlled to the DAC and ALARA.¹

What should staff do if xenon is released into the room?

Because inert Xe-133 is not retained in the body and clears quickly, the response centers on ventilation and evacuation: leave the room, let the exhaust dilute and clear the gas, and re-enter once concentrations fall below the action level. The gas does not fix to surfaces, so dilution and time are the primary controls.⁴

How is Xe-133 different from Technegas or aerosol agents?

Tc-99m DTPA aerosol and Technegas are particulate agents managed as particulate contamination, and Kr-81m is an ultrashort-lived gas. Xe-133 is a longer-lived true gas that is exhaled and must be trapped or exhausted, which is why xenon studies carry gas-handling requirements the other agents do not.⁵

Key Takeaways

Xe-133 is a radioactive noble gas (half-life about 5.24 days, 81 keV imaging photon) that the patient exhales into the room, making it an airborne rather than surface hazard.⁷
The dominant occupational exposure is external submersion in the gas cloud, controlled by containment, ventilation, and time.¹⁴
The three engineered controls are a charcoal xenon trap, a negative-pressure room, and a controlled exhaust to the outside.⁴⁶
Occupational exposure is controlled to the 10 CFR Part 20 Appendix B submersion DAC ( $1 \times 1 0^{- 4} μ Ci/mL$ ) and ALARA; releases are held to the effluent limit.¹
A room release is cleared by ventilation and evacuation — with adequate air changes, concentrations fall below the DAC in minutes, not hours.
Xe-133's gaseous form and multi-day half-life set it apart from particulate aerosols and ultrashort-lived Kr-81m, which do not need gas capture.⁵

How DRPS Can Help

Diagnostic Radiation Physics Services (DRPS) supports nuclear medicine facilities with radiation safety officer services, ventilation and negative-pressure verification, airborne-monitoring program design, xenon-room and hot-lab evaluation, effluent and waste guidance, and radiation safety documentation prepared by board-certified medical physicists across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

A xenon program is only as safe as its containment and ventilation. Treating the gas, the room, and the exhaust as one engineered system — verified and documented — is what keeps staff dose low and the program defensible.

Conclusion

A xenon-133 ventilation study is a reminder that radiation safety is not one-size-fits-all: a gaseous radionuclide demands engineered containment and ventilation rather than the surface-contamination controls used for liquids and particulates. With a working charcoal trap, a negative-pressure room, controlled exhaust, air monitoring, and a clear release procedure — all anchored to the airborne limits of 10 CFR Part 20 — a facility can offer xenon imaging safely and defensibly.¹²⁴⁶

Related Resources

References

U.S. Nuclear Regulatory Commission. 10 CFR Part 20, Standards for Protection Against Radiation (including Appendix B, occupational values and effluent concentrations). nrc.gov
U.S. Nuclear Regulatory Commission. Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Medical Use Licenses. NUREG-1556, Volume 9, Revision 3. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35, Medical Use of Byproduct Material. nrc.gov
Parker JA, Coleman RE, Grady E, et al. SNM practice guideline for lung scintigraphy 4.0. J Nucl Med Technol. 2012;40(1):57-65. doi:10.2967/jnmt.111.101386. doi.org
Bajc M, Neilly JB, Miniati M, Schuemichen C, Meignan M, Jonson B. EANM guidelines for ventilation/perfusion scintigraphy: Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med Mol Imaging. 2009;36(8):1356-1370. doi:10.1007/s00259-009-1170-5. doi.org
National Council on Radiation Protection and Measurements. Operational Radiation Safety Program. NCRP Report No. 127. Bethesda, MD: NCRP; 1998. ncrponline.org
National Nuclear Data Center, Brookhaven National Laboratory. NuDat / decay data for xenon-133. nndc.bnl.gov
International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 128. Ann ICRP. 2015;44(2 Suppl). icrp.org
National Council on Radiation Protection and Measurements. Radiation Protection for Medical and Allied Health Personnel. NCRP Report No. 105. Bethesda, MD: NCRP; 1989. ncrponline.org
International Atomic Energy Agency. Applying Radiation Safety Standards in Nuclear Medicine. Safety Reports Series No. 40. Vienna: IAEA; 2005. iaea.org